Allan Camaisa - 12 Dec 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Reporting relationship: Director
Issuer ticker: CLDI
Reported as of: 12 Dec 2025
Net transaction value: -$1,237
SEC form: 4
Accepted by SEC: 16 Dec 2025, 19:37:06 UTC
Prior SEC filing: 18 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Andrew Jackson, Attorney-in-fact

Key filing fact

Allan Camaisa filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 16 Dec 2025.

Key facts

This page summarizes Allan Camaisa's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Dec 2025, 19:37.

Change

Previous filing in this sequence was filed on 18 Dec 2024.
Current net transaction value: -$1,237.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001990674 Primary reporting owner

Camaisa Allan

Relationship: Director
Address: C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
Signature: /s/ Andrew Jackson, Attorney-in-fact
Signature date: 16 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLDI transaction

Common Stock

Sale

Transaction value: $1,237
Shares: -850
Change %: -1.1%
Price: $1.46
Shares after: 76,952
Date: 12 Dec 2025
Ownership: AJC Capital, LLC
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The sales reported in this Form 4 were effected for estate and tax planning purposes by AJC Capital, LLC ("AJC"). The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer.

Footnote F2

Includes (i) 6,394 shares of Common Stock directly held by Allan Camaisa, (ii) 19,860 shares of Common Stock held by AJC, and (iii) 50,698 shares of Common Stock held by Jamir Trust.

Footnote F3

Does not include, (i) 1,526 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by Mr. Camaisa, (ii) 3,915 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, and (iii) 22,887 shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by AJC.

Footnote F4

Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa is deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.

Footnote F5

All share and share related information gives retrospective effect to the 1-for-12 reverse stock split effective on August 4, 2025.